| Literature DB >> 29880692 |
Thuy T M Ngo1, Mira N Moufarrej1, Marie-Louise H Rasmussen2, Joan Camunas-Soler1, Wenying Pan1, Jennifer Okamoto1, Norma F Neff1, Keli Liu3, Ronald J Wong4, Katheryne Downes5, Robert Tibshirani3,6, Gary M Shaw4, Line Skotte2, David K Stevenson4, Joseph R Biggio7, Michal A Elovitz5, Mads Melbye8,9, Stephen R Quake10.
Abstract
Noninvasive blood tests that provide information about fetal development and gestational age could potentially improve prenatal care. Ultrasound, the current gold standard, is not always affordable in low-resource settings and does not predict spontaneous preterm birth, a leading cause of infant death. In a pilot study of 31 healthy pregnant women, we found that measurement of nine cell-free RNA (cfRNA) transcripts in maternal blood predicted gestational age with comparable accuracy to ultrasound but at substantially lower cost. In a related study of 38 women (23 full-term and 15 preterm deliveries), all at elevated risk of delivering preterm, we identified seven cfRNA transcripts that accurately classified women who delivered preterm up to 2 months in advance of labor. These tests hold promise for prenatal care in both the developed and developing worlds, although they require validation in larger, blinded clinical trials.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29880692 DOI: 10.1126/science.aar3819
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728